Caspase inhibitors and uses thereof

Details Caspase inhibitors and uses thereof Caspase inhibitors and uses thereof

2009-09-18

2011-12-06

Davis, Zinna Northington (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S141000

Reexamination Certificate

active

08071618

ABSTRACT:
The present invention provides a compound of formula I:wherein:X is —OR1or —N(R5)2,Y is halo, trifluorophenoxy, or tetrafluorophenoxy;R1is:C1-6straight chained or branched alkyl, alkenyl, or alkynyl, wherein the alkyl, alkenyl, or alkynyl is optionally substituted with optionally substituted aryl, CF3, CI, F, OMe, OEt, OCF3, CN, or NMe2;C1-6cycloalkyl, wherein 1-2 carbon atoms in the cycloalkyl is optionally replaced with —O— or —NR5—;R2is C1-6straight chained or branched alkyl;Art Unit 1625R3is hydrogen, halo, OCF3, CN, or CF3;R4is hydrogen, halo, OCF3, CN, or CF3; andeach R5is independently H, C1-6straight chained or branched alkyl, aryl, —O—C1-6straight chained or branched alkyl, or —O-aryl. The present invention also provides pharmaceutical compositions and methods using such compositions for treating a caspase-mediated disease, particularly in the central nervous system.

REFERENCES:
patent: 4728647 (1988-03-01), Benavides et al.
patent: 5656627 (1997-08-01), Bemis et al.
patent: 5716929 (1998-02-01), Bemis et al.
patent: 5756466 (1998-05-01), Bemis et al.
patent: 5847135 (1998-12-01), Bemis et al.
patent: 5973111 (1999-10-01), Bemis et al.
patent: 6025147 (2000-02-01), Bemis et al.
patent: 6103711 (2000-08-01), Bemis et al.
patent: 6420522 (2002-07-01), Bemis et al.
patent: 6525076 (2003-02-01), Zhu et al.
patent: 7612091 (2009-11-01), Charrier et al.
patent: 2003/0162993 (2003-08-01), Mortimore et al.
patent: 2004/0019017 (2004-01-01), Mortimore et al.
patent: 2004/0048797 (2004-03-01), Miller et al.
patent: 2004/0242494 (2004-12-01), Brenchley et al.
patent: 232699 (1986-02-01), None
patent: 0761680 (1997-12-01), None
patent: 1203766 (2002-05-01), None
patent: 95/35308 (1995-12-01), None
patent: 9603982 (1996-02-01), None
patent: 96/40647 (1996-12-01), None
patent: 97/22619 (1997-06-01), None
patent: 98/16502 (1998-04-01), None
patent: 98/16505 (1998-04-01), None
patent: 98/18781 (1998-05-01), None
patent: 00/67746 (2000-11-01), None
patent: 00/68188 (2000-11-01), None
patent: 01/42216 (2001-06-01), None
patent: 01/94351 (2001-12-01), None
patent: 03042169 (2003-05-01), None
patent: 03/068242 (2003-08-01), None
patent: 2004/002961 (2004-01-01), None
patent: 2004/058718 (2004-07-01), None
patent: 2006/005796 (2006-06-01), None
Dec. 27, 2004 Office Action from U.S. Appl. No. 10/609,147.
Jun. 12, 2003 Office Action from U.S. Appl. No. 10/166,437.
Feb. 26, 2004 Office Action from U.S. Appl. No. 10/166,437.
Jan. 26, 2007 Office Action from U.S. Appl. No. 10/166,437.
Golec, et al., “Structure-Based Design on Non-Peptidic Pyridone Aldehydes as Inhibitors of Interleukin-1β Converting Enzyme”, Bioorganic & Medicinal Chemistry Letters (1997), vol. 7, No. 17, pp. 2181-2186.
Semple, et al., “Peptidomimetic Aminomethylene Ketone Inhibitors of Interleukin-1β-Converting Enzyme (ICE)”, Bioorganic & Medicinal Chemistry Letters (1998), vol. 8, pp. 959-964.
Semple, G., et al., “Pyridone-Based Peptidomimetic Inhibitors of Interleukin-1β-Converting Enzyme (ICE),” Bioorganic & Medicinal Chem. Letters, vol. 7, No. 10, pp. 1337-1342 (1997).
Livingston, D.J., “In Vitro and In Vivo Studies of Ice Inhibitors,” J. of Cell. Biochem., 64(1):19-26 (1997).
Husain, M.I. and Singh, E., “Some New 2-Aryloxymethyl-3-alpha-substituted Carboxymethyl-6,8-substituted-4-Quinazolones As Possible Anticonvulsants,”, Pharmazie, 37(6):408-410 (1982).
Hussian, M.I. and Amir, M., “Some Newer Quinazolones as Possible Anticonvulsants,” J. Chem. Soc. Pak, 6 (4):211-215 (1984).
Canonne, P., et al., “Synthesis of chiral 3-substituted 2,4(1H,3H)-quinazolinediones,” Heterocycles, 36(6):1305-1314 (1993).
Gouilleux, L, et al., “Solid Phase Synthesis of Chiral 3-substituted Quinazoline-2, 4-diones,” Tetrahedron Letters, 37 (39):7031-7034 (1996).
Gordeev, M.F., et al., “A General and Efficient Solid Phase Synthesis of Quinazoline-2, 4-diones,” Tetrahedron Letters, 38(10):1729-1732 (1997).
Prokai-Tatrai, K., et al., “Prodrugs to Enhance Central Nervous System Effects of TRH-like Peptide pGlu-Glu-Pro-NH2,” Bioorg. Med. Chem. Lett., 13:1011-1014 (2003).
Narasimhan, R.S., “Synthetic Application of Lithiation Reactions; IX. A Simplified Synthesis of Isocoumarin,” Synthesis, 12: 797 (1975).
Kinder, M.A., et al., “Solid State Photochemistry of Isocoumarins and Isothiocoumarins,” Tetrahedron 56: 6763-6767 (2000).
Revesz, L., et al., “Synthesis of P1 Aspartate-Based Peptide Acyloxymethyl and Fluoromethyl Ketones as Inhibitors of Interleukin-1β-Converting Enzyme,” Tetrahedron Letters, 35 (52):9693-9696 (1994).
Golstein, P., “Cell death in us and others”, Science, 281 (5381), 1283 (1998).
Ellis, et al., “Mechanisms and functions of cell death”, Annual Review Cell Biology, 7, 663 (1991).
Thornberry, N.A., “Key Mediators of Apoptosis”, Chemical Biology, 5, R97-R103 (1998).
Yaoita, H., et al., “Attenuation of ischemia/reperfusion injury in rats by a caspase inhibitor”, Circulation, 97, 276-281 (1998).
Endres, M., et al., “Attenuation of delayed neuronal death after mild focal ischemia in mice by inhibition of the caspase family”, Journal of Cerebral Blood Flow and Metabolism, 18, 238-247 (1998).
Cheng, Y., et al., “Caspase inhibitor affords neuroprotection with delayed administration in a rat model of neonatal hypoxic-ischemic brain injury”, Journal of Clinical Investigation, 101, 1992-1999 (1998).
Yakovlev, A.G., et al., “Activation of CPP32-like caspases contributes to neuronal apoptosis and neurological dysfunction after traumatic brain injury”, The Journal of Neuroscience, 17, 7415-7424 (1997).
Rodriguez, I., et al., “Systemic injection of a tripeptide inhibits the intracellular activation of CPP32-like proteases in vivo and fully protects mice against fas-mediated fulminant liver destruction and death”, Journal of Experimental Medicine, 184, 2067-2072 (1996).
Grobmyer, S.R., et al., “Peptidomimetic fluoromethylketone rescues mice from lethal endotoxic shock”, Molecular Medicine, 5, 585-594 (1999).
Plattner, J.J., et al., “Obstacles to Drug Development from Peptide Leads”, Drug Discovery Technologies, ch. 5, pp. 93-126 (1990).
Wilson, K., et al., “Structure and mechanism of interleukin-1β converting enzyme”, 370, 270-275 (1994).
Lazebnik, Y.A., et al., “Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE”, Nature, 371, 346-347 (1994).
Greig, N.H., et al., “Physicochemical and pharmacokinetic parameters of seven lipophilic chlorambucil esters designed for brain penetration”, Cancer Chemotherapy, 25, 311-319 (1990).
Tejani-Butt, S.M., et al., “Evaluation of mono-and dibenzoyl esters of dopamine as potential pro-drugs for dopamine in the central nervous system”, Arch. Pharmacology, 338(5):497-503 (1988).
Prokai-Tatrai, K., et al., “Brain-targeted delivery of a leucine-enkephalin analogue by retrometabolic design”, J. Med. Chem., 39, 4775-4782 (1996).
Ishikura, T., et al., “Drug delivery to the brain. DOPA prodrugs based on a ring-closure reaction to quaternary thiazolium compounds”, Int. J. Pharmaceutics, 116, 51-63 (1995).
Bonina, F.P., et al., “Synthesis, stability, and pharmacological evaluation of nipecotic acid prodrugs”, J. Pharm. Sci., 88(5):561-567 (1999).
Battaglia, G., et al., “Systemically administered d-glucose conjugates of 7-chlorokynurenic acid are centrally available and exert anticonvulsant activity in rodents”, Brain Res., 860, 149-156 (2000).
Caba, J.M., et al., “Solid-phase total synthesis of trunkamide A”, J. Org. Chem., 66, 7568-7574 (2001).
Schierle, G., et al., “Caspase inhibition reduces apoptosis and increases survival of nigral trans

Affiliated with

Also associated with

Rating

Caspase inhibitors and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Caspase inhibitors and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Caspase inhibitors and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4309723